PE/Cyanine7 anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
MEL-14_PECy7_090707
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) PE/Cyanine7 (filled histogram) or rat IgG2a PE/Cyanine7 isotype control (open histogram).
  • MEL-14_PECy7_090707
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) PE/Cyanine7 (filled histogram) or rat IgG2a PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability
104417 25 µg $88.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104418 100 µg $215.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Oh–Hora M, et al. 2019. J Immunol. 202:2616. PubMed
  2. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  3. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  4. Ye ZW, et al. 2022. Cell Mol Immunol. 19:588. PubMed
  5. Broadfield LA, et al. 2022. Mol Metab. 61:101498. PubMed
  6. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  7. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  8. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  9. Cheng H, et al. 2023. Nat Metab. 5:314. PubMed
  10. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  11. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  12. De Giovanni M, et al. 2022. Cell. 185:815. PubMed
  13. Hu Y, et al. 2022. Front Immunol. 13:1022011. PubMed
  14. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  15. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  16. Falahat R, et al. 2023. Nat Commun. 14:1573. PubMed
  17. Ito M, et al. 2023. Sci Rep. 13:5939. PubMed
  18. Corria-Osorio J, et al. 2023. Nat Immunol. 24:869. PubMed
  19. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  20. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
  21. Hu Y, et al. 2023. JCI Insight. 8:. PubMed
  22. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  23. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  24. Gerber AN, et al. 2021. Cell Rep. 37:109816. PubMed
  25. Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed
  26. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  27. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
  28. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  29. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  30. Huang W, et al. 2014. J Immunol. 193:2267. PubMed
  31. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  32. Kinder JM, et al. 2020. Cell Reports. 31(12):107784.. PubMed
  33. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  34. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  35. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  36. Nguyen T, et al. 2017. Clin Transl Immunology. 10.1038/cti.2017.4. PubMed
  37. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  38. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  39. Gordon RA, et al. 2020. PLoS One. 15:e0226396. PubMed
  40. Li B, et al. 2015. Sci Rep. 5: 14793. PubMed
  41. Hirose M, et al. 2011. Biochem Biophys Res Commun. 414:437. PubMed
  42. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  43. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  44. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  45. He X, et al. 2021. Small. 17:e2007165. PubMed
  46. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  47. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  48. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  49. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  50. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  51. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  52. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  53. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  54. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  55. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  56. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  57. Stenström M, et al. 2010. Int Immunopharmacol. 10:837. PubMed
  58. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  59. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  60. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  61. Masiuk KE, et al. 2019. Cell Stem Cell. 24:309. PubMed
  62. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  63. DiPiazza AT, et al. 2021. Immunity. 54(8):1869-1882.e6. PubMed
  64. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  65. Li G, et al. 2021. Front Oncol. 11:734593. PubMed
  66. Corbett KS, et al. 2020. Nature. 586:567. PubMed
  67. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  68. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  69. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  70. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  71. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  72. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  73. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  74. Severance AL, et al. 2022. iScience. 25:104400. PubMed
  75. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  76. Motwani MP, et al. 2018. JCI Insight. 3:e94463. PubMed
  77. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  78. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  79. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  80. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  81. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  82. Danzer H, et al. 2020. Elife. 9:00. PubMed
  83. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  84. Werner A, et al. 2021. iScience. 24:103076. PubMed
  85. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
  86. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  87. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  88. Kitamoto S, et al. 2020. Cell. 182(2):447-462.e14. PubMed
  89. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  90. Seeling M, et al. 2013. Proc Natl Acad Sci U S A. 110:10729. PubMed
  91. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  92. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  93. Gonzalez MM, et al. 2021. J Clin Invest. 131:. PubMed
  94. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  95. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  96. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  97. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  98. BJ L, et al. 2017. J Exp Med . 10.1084/jem.20161461. PubMed
  99. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
RRID
AB_313102 (BioLegend Cat. No. 104417)
AB_313102 (BioLegend Cat. No. 104418)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account